Here, we used multiplexed quantitative immunofluorescence (QIF) to assess the distribution and patterns of expression of both CD200 and CD200R in three independent lung cancer cohorts and evaluate their association with clinicopathologic characteristics, mutation status, outcome, and PD-L1 expression. This evidence concerns the gene CD200 and lung cancer.